 Bossy
"I've no idea whether 1GW has multiple id's or not .But if you are correct it at last explains why people keep posting bullish comments even when the reality has been clearly pointed out and starting to be priced in"
Exactly. The company newsflow was as expected. Yet 1gw and his mates always post the metric which make it sound like the best share. In this case Octopus must know more than the chairman!!!
I find it extremely difficult to believe that someone, who portrays themselves as well researched can have virtually all his shares crash. Virtually all his stories/suggestions turn out to be false...
Look at TLY. 1gw posted a lot of BS and made it sound like plausible outcomes, even though it was clear that it was BS.
On Byot: to prove 1gw and his mates talk BS... I bought Byot shares at around 1.8p, whilst maintaining a negative stance and stating that the reason I bought was because 1gw and his mates are pumping the. I then sold them at around 8p. The shares delisted at 0.01p
GBO bust
STU bust
Nano down 70%
Byot down 99.9%
INSE
NTQ
etc
etc
TLY have recently won around £20m of contracts. Mcap of £15m. Look at the stories being posted on the TLY thread!!! |
Yump - 62 less 35 is 27 and 6 of this Venn (not challenge trials) and there will be some for lab services. Order book probably around £55m at the least (just added £11.5 to it) so probably over £60m |
Yump, difficult to argue with you although many will no doubt.. |
Perhaps worth summarising:
This year 62mln on track.
£35 mln at interims.
71mln order book at interims.
Therefore 27mln of the 71mln will be gone at year end.
Leaving 44mln for 2025 assuming all of it will be for 2025 which seems reasonable.
So, another 23mln needed in 2025 to reach forecast.
Add on contracts after interims (whatever proportion you fancy). Say 5mln.
Add on unknown invisible contract value (small ones not announced).
Have a guess at what’s needed to be announced and started in 2025, or partly paid up front.
I reckon worst case could be 20mln short atm. To get that, perhaps 40mln of contracts needed, so half can hit in 2025, meeting targets.
Not impossible but seems a stretch. |
2025 forecast are revenue of circa 67m . How can you not know that ?
Give over |
My dear fellow , you are a shareholder in the company and you can't work it out !!
Honestly , I beg you ... learn how the cash flow works for this business and do some proper research .. this is crazy stuff |
Bossyboss - interesting that you don’t think 2025 forecasts can be met. Have you been advised of forecasts? What are they - please update us. On cash Hvivo had £37m at the end of H1 they also had a very large debtor at the end of H1 for revenues invoiced right at the end of the period - this debtor will be paid in H2. The Company including Venn will be invoicing lots of smaller sized work undertaken in H2 - (and running costs for H2 will be around £23m) - how do you get a negative cash burn of £12m |
Silk , I've no idea whether 1GW has multiple id's or not .But if you are correct it at last explains why people keep posting bullish comments even when the reality has been clearly pointed out and starting to be priced in .
I struggle to understand how anyone still thinks that revenue forecasts for 2025 can realistically be met . They probably don't and are now focusing on 2028 which is nothing short of ridiculous behaviour .
How can anyone not understand that the year end cash figure will be down to the mid 20 's ?? It's not that difficult to calculate !
These shares could well go a lot lower.
DYOR |
'Super,
Yet another share ramped by you'
Liar, liar, pants on fire... |
I did warn PIs to be aware of 1gw and his mates. They have a long history of ramping, dumping and then disappearing.
1gw,
There you go, multiple faces of 1gw and his mates....
TLY published their interims on time 6 weeks ago!!
Your concern is that they haven't answered your questions, which were twisted questions to suit your agenda. No comments over the multi million pound contracts. Just why TLY haven't answered your question this time around.
Yet on shares you and your mates continuously ramp...
These 4 shares over just past TWO weeks
Byot:
Byot have POSTPONED their ENTIRE interims. Something I warned they have a history of doing.
Yet on there you have no comments or concerns on the entire interims being postponed. Let alone any q&A.
NTQ:
They were LATE on publishing interims.
Then they went on and had to publish their interims TWICE as they had errors.
Yet you don't see any concerns there either!! From cash balance obviously looks like placing soon
Yet you make no comments on the interims being published twice
Inse:
Like your other ramps, a company full of jam tomorrow but little substance.
They announced a placing resulting in significant dilution.
HVO:
They announced a £11m contract but not long ago they were talking about £40m contracts soon. £150m mcap.
They also DELAYED their fy TU by over a month.
Yet you talk about 'big contract' and make NO comments on the delayed fy TU.
1gw, Given you portray yourself as a well researched poster, why do virtually all your and your mates shares crash? Why do virtually all your/your mates stories, suggestions turn out to be false and misleading?
Why are you not concerned about delayed interims or company having to publish it multiple times?
How many multiple id do you have and why?
You make a dodgy 2nd hand car salesman sound honest, don't you? |
Super,
Yet another share ramped by you, 1gw and mates which is falling back on company newsflow, which I warned about. |
posts on tly too. What does it all mean? |
There you go,
Nexn thread busy, HVO quiet.
The blnx pump and dump gang with their multiple ids.
Is it a coincidence that 1gw posts on both?? |
I don't think many people are perfect. The guy speaks the truth. Sometimes that hurts. I just hope that he doesn't get hurt for exposing the truth. |
On food additives yes, but vaccines that's a whole different story. |
I'm not surprised. He tells the truth. The big boys won't want that. |
This is a key area on the chart here. A close below 21p will see price test 18-19p area. People are getting bored here. |
There seems to be more push back in Congress about RFK Jnr.
All they need are 3 Republican's to vote Nay. |
This time in 2028 Rodney.... |
STT you really do seem to spread your bile on a lot of bb’s….. chill mate, don’t let it get to you |
Sounds a bit desperate to me |
Interesting an email I received this morning from the horses mouth.Looks like Mo's on a mission to drum up business.
Dear ,
We are pleased to share that our colleagues at hVIVO have been featured in Nature Communications with a peer-reviewed paper titled “SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections”.
;
This publication builds on the groundbreaking insights from the world’s first COVID-19 characterisation trial we conducted in 2021 in collaboration with Imperial College London, the UK Vaccine Taskforce, the Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust.
Read the full article here: Nature Communications
The study identified key biomarkers in the blood activated, not only in SARS-CoV-2 infection but also in other respiratory viruses, that can identify and distinguish between the early and late phases of infection. These biomarkers could provide a basis for advancements in infection diagnosis and management in early and late-stage infections.
Human challenge trials allow researchers to observe infection progression, particularly in the early stages, in detail that would not be possible with a traditional field study. Excitingly, the early-stage marker was observable sometimes even before PCR testing confirmed the presence of the virus, suggesting future clinical utility in inferring the infectiousness of a patient early in the infection time-course as well as a potential role in helping stratify patients for antiviral therapy.
We are delighted to see that hVIVO’s impactful contributions during the COVID pandemic continue to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses.
If you’d like to discuss how our expertise in human challenge trials could help support the clinical development of your drug candidates, or to learn more on our expanded laboratory and site study services, then please reach out at BD@hvivo.com.
Kind regards,̴3;
Yamin 'Mo' Khan
CEO |
You're now repeating the same dirge, so in the bin for you. I'm all for different opinions, but yours has got a bit excessive now... |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
